Brian Rader, M.S, NCC, LAC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 312 Applegarth Rd Ste 200, Monroe Township, NJ 08831 Phone: 732-655-4239 |
Christina Lavigne Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1 Shinnecock Ct, Monroe Township, NJ 08831 Phone: 609-424-6535 |
Ms. Kataura Toi Washington-simon Counselor Medicare: Not Enrolled in Medicare Practice Location: 1148 Morning Glory Dr, Monroe Township, NJ 08831 Phone: 646-526-3224 |
Laura Dicarlo, LAC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 312 Applegarth Rd Ste 200, Monroe Township, NJ 08831 Phone: 732-655-4239 |
Grishma Patel Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 24 Larkspur Ln, Monroe Township, NJ 08831 Phone: 267-418-9135 |
Ms. Ellen Brody, LAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 312 Applegarth Rd, Monroe Township, NJ 08831 Phone: 732-655-4239 Fax: 732-444-3120 |
Jason Zagaro Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 312 Applegarth Rd, Monroe Township, NJ 08831 Phone: 773-308-5030 |
Tina Marie Cisco, MS, LAC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 312 Applegarth Rd Ste 200, Monroe Township, NJ 08831 Phone: 732-655-4239 |
News Archive
Colorcon Inc. and Evonik Industries AG have announced the signing of a cooperation agreement for the marketing and technical support of Acryl-EZEĀ®, aqueous acrylic enteric system.
The novel coronavirus pandemic has nearly exhausted stockpiles of medical gear in the United States. Personal protective equipment, like masks, serve as a first-line defense for medical professionals with a front row seat to COVID-19.
On November 9, 2009, Honorable Speaker of the Senate Ron Ramsey, and Honorable Senator Mark Norris issued the first proclamation in support of a Mental Health initiative in the state of Tennessee. This is a major breakthrough to benefit people living with bipolar disorder in the State of Tennessee, and support The Brilliance in Bipolar Initiative.
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
› Verified 9 days ago